Yujin Hoshida MD PhD
Hepatology & Liver Transplantation
Professor of Internal Medicine, Director of Liver Tumor Translational Research
Join to View Full Profile
5323 Harry Hines BlvdDallas, TX 75390
Phone+1 214-648-3111
Dr. Hoshida is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Yujin Hoshida is a gastroenterologist and physician scientist based in Dallas, TX, with subspecialties in hepatology and translational research. He graduated in 1994 and has contributed to several notable publications focusing on hepatocellular carcinoma (HCC), including works on biomarkers for precision HCC screening and therapeutic and preventive targets and agents for HCC. His research in the field has been widely cited, highlighting his contributions to understanding liver diseases and cancer prevention. Dr. Hoshida is also involved in clinical trials, serving as Principal Investigator for studies on chemoprevention and the efficacy of agents like EGCG and Atorvastatin in reducing HCC risk.
Education & Training
OtherClass of 1994
Clinical Trials
- National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Start of enrollment: 2021 Jul 28
Roles: Contact
- Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk Start of enrollment: 2023 May 10
Roles: Principal Investigator, Contact
- Erlotinib for Hepatocellular Carcinoma Chemoprevention
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 38 citationsRisk stratification and early detection biomarkers for precision HCC screening.Yi-Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida
Hepatology. 2023-07-01 - Precision HCC Surveillance: It Is All in the Number (Needed).Amit G Singal, Neehar D Parikh, Yujin Hoshida
Digestive Diseases and Sciences. 2023-03-01 - 23 citationsTreatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.Natascha Roehlen, Marion Muller, Zeina Nehme, Emilie Crouchet, Frank Jühling
Journal of Hepatology. 2023-02-01
Press Mentions
MedBlog Cancer; Digestive; Discovery Taking Aim at Fatty Liver, Cancer With New Blood TestSeptember 7th, 2022- A Simple Blood Test Reliably Predicts the Development of Liver Cancer – Healing PracticeJune 24th, 2022
- UTSW Researchers Identify a New Biomarker to Assess Your Risk of Liver CancerJune 6th, 2022
- Join now to see all
Grant Support
- Epigallocatechin gallate for prevention of lethal cirrhosis complicationsUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Epigallocatechin gallate for prevention of lethal cirrhosis complicationsUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Epigallocatechin gallate for prevention of lethal cirrhosis complicationsUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosisUT SOUTHWESTERN MEDICAL CENTER2023–2027
- Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosisUT SOUTHWESTERN MEDICAL CENTER2023–2027
- Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosisUT SOUTHWESTERN MEDICAL CENTER2023–2027
- Trial of Statins for Chemoprevention in Hepatocellular CarcinomaMASSACHUSETTS GENERAL HOSPITAL2021–2027
- Trial of Statins for Chemoprevention in Hepatocellular CarcinomaMASSACHUSETTS GENERAL HOSPITAL2021–2027
- Trial of Statins for Chemoprevention in Hepatocellular CarcinomaMASSACHUSETTS GENERAL HOSPITAL2021–2027
- Glycopathology of HCC: identification of the source cells of serum fucosylationMEDICAL UNIVERSITY OF SOUTH CAROLINA2019–2025
- Reverse-engineering precision liver cancer chemopreventionUT SOUTHWESTERN MEDICAL CENTER2019–2025
- Reverse-engineering precision liver cancer chemopreventionUT SOUTHWESTERN MEDICAL CENTER2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
